Published in J Rheumatol on September 01, 2002
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging (2009) 1.62
Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3. Proc Natl Acad Sci U S A (2004) 1.38
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest (2008) 1.27
Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov (2009) 1.10
Update in the mechanisms of allergen-specific immunotheraphy. Allergy Asthma Immunol Res (2010) 1.07
Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood (2009) 1.03
The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol (2010) 1.03
Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther (2009) 0.97
Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis. Results Probl Cell Differ (2010) 0.96
New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci (2008) 0.93
New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci (2010) 0.84
Induction of immunological tolerance by oral anti-CD3. Clin Dev Immunol (2011) 0.84
In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun (2008) 0.84
T cell tolerance induced by therapeutic antibodies. Philos Trans R Soc Lond B Biol Sci (2005) 0.81
Induction of active tolerance and involvement of CD1d-restricted natural killer T cells in anti-CD3 F(ab')2 treatment-reversed new-onset diabetes in nonobese diabetic mice. Am J Pathol (2008) 0.81
Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. Blood (2012) 0.80
Engineered CD3 antibodies for immunosuppression. Clin Exp Immunol (2003) 0.80
Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev (2014) 0.80
Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells. Clin Immunol (2011) 0.79
The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. Semin Immunopathol (2012) 0.78
Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J Immune Based Ther Vaccines (2005) 0.78
Natural killer cells modulate overt autoimmunity to homeostasis in nonobese diabetic mice after anti-CD3 F(ab')2 antibody treatment through secreting transforming growth factor-beta. Am J Pathol (2009) 0.78
Characterization of a surrogate murine antibody to model anti-human CD3 therapies. MAbs (2013) 0.77
Treating arthritis by immunomodulation: is there a role for regulatory T cells? Rheumatology (Oxford) (2010) 0.77
Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther (2010) 0.76
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
GATA-3: an unexpected regulator of cell lineage determination in skin. Genes Dev (2003) 2.97
Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med (2006) 2.35
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
HS1 functions as an essential actin-regulatory adaptor protein at the immune synapse. Immunity (2006) 2.23
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13
CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
B cell antigen receptor signaling and internalization are mutually exclusive events. PLoS Biol (2006) 1.85
Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
Murine pancreatic islet isolation. J Vis Exp (2007) 1.68
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67
A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63
Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61
Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat Immunol (2011) 1.59
Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55
IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54
Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) (2011) 1.54
In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol (2010) 1.54
A unique function for cyclin D3 in early B cell development. Nat Immunol (2006) 1.51
The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49
Ras orchestrates exit from the cell cycle and light-chain recombination during early B cell development. Nat Immunol (2009) 1.48
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45
Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol (2010) 1.42
Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol (2013) 1.42
CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells. J Immunol (2009) 1.40
Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39
Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol (2008) 1.30
Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29
Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp (2007) 1.28
Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27
The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med (2011) 1.26
TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol (2009) 1.26
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol (2008) 1.25
When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol (2002) 1.25
Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol (2003) 1.25
Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25
CTLA-4 and tolerance: the biochemical point of view. Immunol Res (2003) 1.24
Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol (2013) 1.24
The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol (2002) 1.24
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23